News & Updates
Filter by Specialty:
Enzalutamide edges out abiraterone in mCRPC
In the treatment of patients with metastatic castration-resistant prostate cancer (mCRPC), the use of enzalutamide yields small improvements in outcomes when compared with abiraterone acetate, according to a retrospective study.
Enzalutamide edges out abiraterone in mCRPC
15 Sep 2024
Conservative excisional margin for small MIS tied to low recurrence
For small-sized melanoma in situ (MIS; <10 mm) on low-risk body sites, wide local excision (WLE) using a 5-mm margin was associated with a low rate of recurrence, a retrospective case series study has shown.
Conservative excisional margin for small MIS tied to low recurrence
09 Sep 2024
Add-on acalabrutinib prolongs PFS in older patients with untreated MCL
In older patients with untreated mantle cell lymphoma (MCL), the addition of the Bruton tyrosine kinase (BTK) inhibitor acalabrutinib to bendamustine and rituximab (ABR) conferred a statistically significant and clinically meaningful improvement in progression-free survival (PFS) with a favourable trend for overall survival (OS), findings from the phase III ECHO trial have shown.
Add-on acalabrutinib prolongs PFS in older patients with untreated MCL
04 Sep 2024
In Asia, being heavier takes a toll on CRC incidence, mortality
A strong, positive link between BMI and the risk of colorectal cancer (CRC) incidence and related deaths has been found in Asian populations.
In Asia, being heavier takes a toll on CRC incidence, mortality
02 Sep 2024
STAMP inhibitor bests all TKIs in pivotal head-to-head CML study
In the phase III ASC4FIRST study, asciminib – the first BCR::ABL1 inhibitor to Specifically Target the ABL Myristoyl Pocket (STAMP) – trumped all investigator-selected tyrosine kinase inhibitors (IS-TKIs; imatinib, nilotinib, dasatinib, and bosutinib) for the treatment of newly diagnosed Philadelphia chromosome-positive chronic myeloid leukaemia in chronic phase (Ph+ CML-CP).
